Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Giovanni Gabutti. (2022) Available evidence and potential for vaccines for reduction in antibiotic prescriptions. Human Vaccines & Immunotherapeutics 18:7.
Read now
Read now
Randall Severance, Howard Schwartz, Ron Dagan, Laurie Connor, Jianing Li, Alison Pedley, Jonathan Hartzel, Tina M. Sterling, Katrina M. Nolan, Gretchen M. Tamms, Luwy K. Musey & Ulrike K. Buchwald. (2022) Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU). Human Vaccines & Immunotherapeutics 18:1, pages 1-14.
Read now
Read now
Yawen Jiang, Zhaojia Ye, Daqin Chen & Yuelong Shu. (2020) Dual influenza and pneumococcal vaccination was associated with lower short-term risks of all-cause and acute respiratory hospitalizations among the elderly in Shenzhen, China: a retrospective cohort study. Emerging Microbes & Infections 9:1, pages 2578-2587.
Read now
Read now
Seong-Beom Park, Hyun-Jin Kim & Hee-Jin Cheong. (2019) Environmental factors which can affect the burden of pneumococcal disease and the immune response to pneumococcal vaccines: the need for more precisely delineated vaccine recommendations. Expert Review of Vaccines 18:6, pages 587-596.
Read now
Read now
Articles from other publishers (8)
Thi Hao Pham, Ekkehard Beck, Maarten J. Postma, Bertalan Németh, Tamás Ágh, Chiara de Waure, David M. Salisbury, Nynke Nutma & Jurjen van der Schans. (2023) Country score tool to assess readiness and guide evidence generation of immunization programs in aging adults in Europe. Frontiers in Public Health 10.
Crossref
Crossref
Ignacio Hernández-García, Moisés Garcés-Redondo, Joana Rodríguez-Montolio, Irantzu Bengoa-Urrengoechea, Judit Espinosa-Rueda & Carlos Aibar-Remón. (2022) Influenza Vaccination Coverage among Multiple Sclerosis Patients: Evolution over Time and Associated Factors. Vaccines 10:7, pages 1154.
Crossref
Crossref
Min Dou, Wenjun Song, Yongping Lin, Qigao Chen, Chang Lu & Zhongmin Liu. (2022) Clinical characteristics and viral analysis of severe influenza A [H1N1]pdm09 in Guangzhou, 2019. Journal of Medical Virology 94:6, pages 2568-2577.
Crossref
Crossref
Hanyue Ding, Junjie Huang, Chun Ho Ngai, Qingjie Sun, Kin-On Kwok, Harry HX Wang, Marc Chong & Martin CS Wong. (2022) The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study. Vaccine 40:9, pages 1282-1288.
Crossref
Crossref
Álvaro Sosa Liprandi, María Inés Sosa Liprandi, Ezequiel José Zaidel, Gabriel M. Aisenberg, Adrián Baranchuk, Eduardo Costa Duarte Barbosa, Gabriela Borrayo Sánchez, Bryce Alexander, Fernando Tomás Lanas Zanetti, Ricardo López Santi, Ana Girleza Múnera-Echeverri, Pablo Perel, Daniel Piskorz, Carlos Enrique Ruiz-Mori, Jorge Saucedo, Osiris Valdez, José Ramón González Juanatey, Daniel José Piñeiro, Fausto J. Pinto & Fernando Stuardo Wyss Quintana. (2021) Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation. Global Heart 16:1.
Crossref
Crossref
Yangyang Cheng, Xinxi Cao, Zhi Cao, Chenjie Xu, Li Sun, Ying Gao, Yuan Wang, Shu Li, Cunjin Wu, Xin Li, Yaogang Wang & Sean X. Leng. (2020) Effects of influenza vaccination on the risk of cardiovascular and respiratory diseases and all-cause mortality. Ageing Research Reviews 62, pages 101124.
Crossref
Crossref
C. Malainou & S. Herold. (2019) InfluenzaInfluenza. Der Internist 60:11, pages 1127-1135.
Crossref
Crossref
Michael P. Veve & Vasilios Athans. 2019. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
351
372
.